← Back to Search

PSMA and FDG PET Imaging for Prostate Cancer

N/A
Waitlist Available
Led By Di (Maria) Jiang
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial will use special imaging techniques to study advanced prostate cancer in patients. The goal is to understand how the tumors change at different stages of the disease and during treatment. This information could be helpful in

Who is the study for?
This trial is for individuals with advanced prostate cancer. It aims to understand tumor biology using specialized imaging techniques, which could guide treatment choices and monitor responses in the future.Check my eligibility
What is being tested?
The study tests the use of two types of PET scans: Ga 68 PSMA-11 and FDG PET, along with a third type called 18F-DCFPyL PET. These scans are used to visualize cancer activity and may inform better treatment strategies.See study design
What are the potential side effects?
PET scans are generally safe but can include discomfort from injection, allergic reactions to tracers, or exposure to low levels of radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of patients with high volume mCSPC having PSMA avid disease
Secondary outcome measures
Proportion of patients with PSMA-/FDG+ discordant lesions

Trial Design

1Treatment groups
Experimental Treatment
Group I: PSMA and FDG PET ImagingExperimental Treatment3 Interventions
Participants advanced prostate cancer will undergo PSMA and FDG PET prior to starting their standard of care treatment and during treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FDG PET
2017
N/A
~30

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,476 Previous Clinical Trials
485,150 Total Patients Enrolled
64 Trials studying Prostate Cancer
15,400 Patients Enrolled for Prostate Cancer
Di (Maria) JiangPrincipal InvestigatorPrincess Margaret Cancer Centre/University Health Network

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently able to participate in this ongoing medical study?

"As per clinicaltrials.gov, the current trial is not in need of participants. It was initially listed on June 1st, 2024 and last revised on March 21st, 2024. Despite this specific trial not seeking enrollees presently, there exist a total of 1297 other trials actively looking for participants at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
2024. "Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06335914.
All > Advanced Prostate Cancer
~20 spots leftby Mar 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top